Topical Cyclosporine A Therapy in Children With Ocular Rosacea and Phlyctenular Keratoconjunctivitis
Narrative Responses:
Purpose
To assess the efficacy of topical cyclosporine A (CsA) therapy in children with ocular rosacea and phlyctenular keratoconjunctivitis associated with severe steroid-dependent corneal inflammation and not responding to oral antibiotics.
Methods
Topical CsA 0.05 % were given four times daily, initially combined with low dose topical loteprednol therapy for the first 3 weeks. Patients were evaluated with symptoms and ocular redness and corneal inflammation.
Results
This retrospective study included 10 children (16 eyes) with a mean age of 10 years (range, 5 to 14 years). The disease was previously resistant to lid hygiene (all the patients), oral erythromycin (9 patients), and intermittent topical steroids (all patients). Inflammation was controlled in all eyes within the 6 weeks. Inflammation did not recur during CsA therapy with a mean follow-up of 12 ± 7 months. CsA therapy was stopped in eight patients after a mean of 11± 6 months, and no recurrences occurred during follow-up.
Conclusion
Long-term topical CsA0.05% therapy is safe and effective in children with pediatric ocular rosacea associated with severe steroid-dependent corneal inflammation.